BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32813315)

  • 1. The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor: A retrospective study in China.
    Huang J; Zhang Y; Zhen Z; Lu S; Zhu J; Wang J; Sun F; Liu Z; Gao Y; Li H; Zhang Y; Sun X
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28567. PubMed ID: 32813315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
    Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
    J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group.
    Koshinaga T; Takimoto T; Okita H; Tanaka Y; Inoue E; Oue T; Nozaki M; Tsuchiya K; Haruta M; Kaneko Y; Fukuzawa M
    Pediatr Int; 2019 Apr; 61(4):351-357. PubMed ID: 30786111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
    Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
    J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2.
    Parsons LN; Mullen EA; Geller JI; Chi YY; Khanna G; Glick RD; Aldrink JH; Vallance KL; Kim Y; Fernandez CV; Dome JS; Perlman EJ
    Cancer; 2020 Jun; 126(12):2866-2871. PubMed ID: 32267967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral Wilms tumors: Treatment results from a single center.
    Aydın B; Akyüz C; Yalçın B; Ekinci S; Oğuz B; Akçören Z; Yıldız F; Varan A; Kurucu N; Büyükpamukçu M; Kutluk T
    Turk J Pediatr; 2019; 61(1):44-51. PubMed ID: 31559721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
    Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
    Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
    Spreafico F; Gandola L; D'Angelo P; Terenziani M; Collini P; Bianchi M; Provenzi M; Indolfi P; Pession A; Nantron M; Di Cataldo A; Marchianò A; Catania S; Fossati Bellani F; Piva L;
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):348-54. PubMed ID: 21075548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
    van den Heuvel-Eibrink MM; van Tinteren H; Bergeron C; Coulomb-L'Hermine A; de Camargo B; Leuschner I; Sandstedt B; Acha T; Godzinski J; Oldenburger F; Gooskens SL; de Kraker J; Vujanic GM; Pritchard-Jones K; Graf N
    Eur J Cancer; 2015 Mar; 51(4):498-506. PubMed ID: 25592561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blastemal NCAM
    Raved D; Tokatly-Latzer I; Anafi L; Harari-Steinberg O; Barshack I; Dekel B; Pode-Shakked N
    Pathol Res Pract; 2019 Aug; 215(8):152491. PubMed ID: 31202518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1-5: A report from the Children's Oncology Group.
    Iaboni DSM; Chi YY; Kim Y; Dome JS; Fernandez CV
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27430. PubMed ID: 30160355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age is not a prognostic factor in children with Wilms tumor beyond stage I in Africa.
    Aronson DC; Hadley GP
    Pediatr Blood Cancer; 2014 Jun; 61(6):987-9. PubMed ID: 24453084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001.
    Hol JA; Lopez-Yurda MI; Van Tinteren H; Van Grotel M; Godzinski J; Vujanic G; Oldenburger F; De Camargo B; Ramírez-Villar GL; Bergeron C; Pritchard-Jones K; Graf N; Van den Heuvel-Eibrink MM
    PLoS One; 2019; 14(8):e0221373. PubMed ID: 31425556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of TCF3 as potential master regulator in blastemal Wilms tumors.
    Kehl T; Schneider L; Kattler K; Stöckel D; Wegert J; Gerstner N; Ludwig N; Distler U; Tenzer S; Gessler M; Walter J; Keller A; Graf N; Meese E; Lenhof HP
    Int J Cancer; 2019 Mar; 144(6):1432-1443. PubMed ID: 30155889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Teratoid" Wilms Tumor: The Extreme End of Heterologous Element Differentiation, Not a Separate Entity.
    D'Hooghe E; Mifsud W; Vujanić GM
    Am J Surg Pathol; 2019 Nov; 43(11):1583-1590. PubMed ID: 31600178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of Wilms' tumor trial (WT-99) in Shanghai children's medical center].
    Tang JY; Pan C; Xu M; Xue HL; Chen J; Zhao HL; Gu LL; Wang YP
    Zhonghua Er Ke Za Zhi; 2003 Feb; 41(2):131-4. PubMed ID: 14759320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.
    Daw NC; Chi YY; Kim Y; Mullen EA; Kalapurakal JA; Tian J; Khanna G; Geller JI; Perlman EJ; Ehrlich PF; Warwick AB; Grundy PE; Fernandez CV; Dome JS;
    Eur J Cancer; 2019 Sep; 118():58-66. PubMed ID: 31325873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeat nephron-sparing surgery for children with bilateral Wilms tumor.
    Kieran K; Williams MA; McGregor LM; Dome JS; Krasin MJ; Davidoff AM
    J Pediatr Surg; 2014 Jan; 49(1):149-53. PubMed ID: 24439600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.